Notably, both pembrolizumab and ipilimumab/nivolumab showed a trend towards a plateau in the tail of patients’ survival curves, suggesting the possibility of long term responders similar to the previous experience with immunotherapy in melanoma.
← all excerpts
Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives.
1
—
—